Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 3/2/12  and contains information from public web pages.

Speedel Experimenta

Wrong Speedel Experimenta?

Board Member

Phone: (732) ***-****  HQ Phone
Speedel Pharmaceuticals Inc
1661 Route 22 WestP.O. Box 6532
Bridgewater, New Jersey 08807
United States

Company Description: Speedel is a biopharmaceutical company that seeks to create value for patients, partners and investors by developing innovative therapies for cardiovascular and...   more
Web References
Speedel- Speedel is a biopharmaceutical company that creates value for patients, partners and investors by developing innovative therapies for cardiovascular and metabolic diseases.
www.speedel.com, 10 Oct 2008 [cached]
Speedel Experimenta was established in April 2002 as the company's late-stage research unit, with state-of-the-art laboratory facilities at the Innovation Centre in Allschwil, Basel, Switzerland.The strategic rationale for this investment is to increase the company's ability to identify and produce attractive candidate compounds for development and to create in-house intellectual property which complements the portfolio of in-licensed compounds.Experimenta commenced operations in 2002 with 10 employees and this has quickly grown to about 50 scientists and technicians in 2007.There has been a corresponding increase in physical laboratory space from 800 to 1400 square meters, together with significant investment in technical equipment.
...
In April 2003 Experimenta established a research collaboration with an American company, Locus Pharmaceuticals Inc., to design novel renin inhibitors that are a new class of therapy for cardiovascular diseases.This collaboration combines the computational technology of Locus with the chemical lead optimisation expertise of Experimenta.
During 2003 and 2004 Experimenta has added four new technical disciplines to significantly expand its in-house capabilities.The rationale for this development is to ensure that Experimenta reduces the traditional time period taken from first synthesis of a compound to entry into man in a cost-efficient manner, and that it creates broader intellectual property rights and captures more value for the company.
...
Speedel Experimenta is today working on multiple series of novel renin inhibitors.It has already produced excellent results in animal models with the SPP600 and SPP1100 series for lowering blood pressure and improving renal protection.The unit now has the capacity to develop compounds with other modes of action for cardiovascular and metabolic diseases.Speedel is committed to the development of this strategic investment as a platform for the company's continued success.
Speedel share price SPPN CHF131.00 Speedel bond price SPP07 CHF112.95 01 October SPEEDEL DISCLOSES CHANGES IN SIGNIFICANT SHAREHOLDERS 15 August SPEEDEL SHAREHOLDERS ELECT FOUR NOVARTIS OFFICERS AS NEW MEMBERS TO THE BOARD OF DIRECTORS 12 August SPEEDEL ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER 2008 06 August SPEEDEL ANNOUNCES NEW DATE FOR Q2 2008 FINANCIAL REPORTING
Speedel Experimenta was ...
www.speedel.com, 10 Dec 2007 [cached]
Speedel Experimenta was established in April 2002 as the company's late-stage research unit, with state-of-the-art laboratory facilities at the Innovation Centre in Allschwil, Basel, Switzerland.The strategic rationale for this investment is to increase the company's ability to identify and produce attractive candidate compounds for development and to create in-house intellectual property which complements the portfolio of in-licensed compounds.Experimenta commenced operations in 2002 with 10 employees and this has quickly grown to about 50 scientists and technicians in 2007.There has been a corresponding increase in physical laboratory space from 800 to 1400 square meters, together with significant investment in technical equipment.
...
In April 2003 Experimenta established a research collaboration with an American company, Locus Pharmaceuticals Inc., to design novel renin inhibitors that are a new class of therapy for cardiovascular diseases.This collaboration combines the computational technology of Locus with the chemical lead optimisation expertise of Experimenta.
During 2003 and 2004 Experimenta has added four new technical disciplines to significantly expand its in-house capabilities.The rationale for this development is to ensure that Experimenta reduces the traditional time period taken from first synthesis of a compound to entry into man in a cost-efficient manner, and that it creates broader intellectual property rights and captures more value for the company.
...
Speedel Experimenta is today working on multiple series of novel renin inhibitors.It has already produced excellent results in animal models with the SPP600 and SPP1100 series for lowering blood pressure and improving renal protection.The unit now has the capacity to develop compounds with other modes of action for cardiovascular and metabolic diseases.Speedel is committed to the development of this strategic investment as a platform for the company's continued success.
Speedel share price SPPN CHF128.10 Speedel bond price SPP07 CHF101.00 15 August 2007 Q2 Webcast 10 December SPEEDEL ANNOUNCES START OF SPP635 PHASE IIA TRIAL IN DIABETIC PATIENTS 29 November SPEEDEL RECEIVES FIRST COST-OF-GOODS SAVINGS FOR SPP100 14 November SPEEDEL ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER 2007 05 November SPP100 (TEKTURNA/RASILEZ) DECREASES PROTEINURIA IN DIABETIC PATIENTS
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.